EP2392258A1 — Pharma-informatics system
Assigned to Proteus Digital Health Inc · Expires 2011-12-07 · 14y expired
What this patent protects
A system comprising: a control device for altering conductance; and a partial power source comprising: a first material electrically coupled to the control device; and a second material electrically coupled to the control device and electrically isolated from the first material, …
USPTO Abstract
A system comprising: a control device for altering conductance; and a partial power source comprising: a first material electrically coupled to the control device; and a second material electrically coupled to the control device and electrically isolated from the first material, wherein the first and second materials are selected to provide a voltage potential difference as a result of the materials being in contact with a conducting liquid, and wherein the control device alters the conductance between the first and second materials such that the magnitude of the current flow is varied to encode information in a signal radiated by the conducting liquid and the encoded information is remotely detectable by a receiver.
Drugs covered by this patent
- Abilify (aripiprazole) · Generic (originally Otsuka/BMS)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.